Navigation Links
OncoGenex Reports Third Quarter Financial Results
Date:11/4/2010

ncogenex.com. Alternatively, you may access the live conference call by dialing (877) 606-1416 (U.S. & Canada) or (707) 287-9313 (International). A webcast replay will be available approximately two hours after the call and will be archived at the same Web location for 90 days. About OncoGenex
OncoGenex is a biopharmaceutical company committed to the development and commercialization of new cancer therapies that address treatment resistance in cancer patients. OncoGenex has a deep oncology pipeline, with each product candidate having a distinct mechanism of action and representing a unique opportunity for cancer drug development. OncoGenex and Teva Pharmaceuticals have entered a global collaboration and license agreement to develop and commercialize OncoGenex' lead drug candidate, custirsen. Custirsen is currently in Phase 3 clinical development as a treatment in men with metastatic castrate-resistant prostate cancer. The companies plan to begin Phase 3 development of custirsen in first-line treatment of advanced, unresectable non-small cell lung cancer in 2011; OGX-427 is in Phase 2 clinical development; SN2310 has completed a Phase 1 clinical trial; and CSP-9222 and OGX-225 are currently in pre-clinical development. More information is available at www.OncoGenex.com. OncoGenex's Forward Looking Statements
This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning our anticipated product development activities, the timing and costs of these activities, the potential benefits of our product candidates, expectations regarding accrual and timing of clinical trials and timing of release of results of studies, and our anticipated future expenses, revenues, reimbursements, capital and sufficiency of capital. All statements other than statements of histo
'/>"/>
SOURCE OncoGenex Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

Related biology technology :

1. OncoGenex Pharmaceuticals, Inc. Closes $50 Million Public Offering
2. OncoGenex Pharmaceuticals, Inc. Prices $50 Million Public Offering
3. OncoGenex Pharmaceuticals, Inc. Announces Proposed Public Offering
4. OncoGenex Pharmaceuticals to Present at the 9th Annual BIO Investor Forum
5. TEVA AND ONCOGENEX ANNOUNCE INITIATION OF SECOND PHASE 3 TRIAL OF CUSTIRSEN IN MEN WITH METASTATIC PROSTATE CANCER
6. OncoGenex Pharmaceuticals, Inc. - Journal of Clinical Oncology Publishes Data from Randomized Phase 2 Custirsen Trial
7. OncoGenex Reports Second Quarter Financial Results
8. OncoGenex Pharmaceuticals Announces Initiation of a Phase 3 Trial in Men with Metastatic Prostate Cancer
9. OncoGenex Pharmaceuticals to Present at the 9th Annual Needham Healthcare Conference
10. OncoGenex Reports First Quarter Financial Results
11. OncoGenex Pharmaceuticals to Webcast Discussion of Financial Results for Fourth Quarter and Fiscal Year 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... At the request of the AMA, the ... for the public comment period (Docket No. FAA-2014-0396) for ... established by Congress as part of the FAA Modernization ... the new deadline for comments as September 23, 2014. ... published in the Federal Register on July 25, 2014, ...
(Date:7/24/2014)... Calif. , July 24, 2014  Now available ... to home. Rehealth Regenerative Therapies , located in ... and other physically active people a new health option: ... Regardless of age, countless patients suffer from joint ... activities, such as muscle tears, torn rotator cuff, tennis ...
(Date:7/24/2014)... to materialise. Yet, scientists are making progress in ... One such approach relies on quantum dotsa kind ... electric field. A new study demonstrates that changing ... (TQDs) with electrical impulses can help better control ... be used as quantum information units, which would ...
(Date:7/24/2014)... Your cell phone may stay charged ... storage capacity. , New research indicates that lithium-ion ... at Lawrence Livermore National Laboratory and ... components will perform as electrodes. , The growing ... for higher-performance batteries. Several key characteristics of lithium-ion ...
Breaking Biology Technology:FAA Grants Comment Extension at the Request of AMA 2Stem Cells In Sports Injuries, Joints And Muscular Pain 2Stem Cells In Sports Injuries, Joints And Muscular Pain 3Getting More Life out of Lithium-ion Batteries 2
... Jan. 6 /PRNewswire-FirstCall/ - Vasogen Inc. (NASDAQ: ... corporate activities. Pursuant to a previously announced restructuring ... the purpose of enhancing shareholder value. This process ... including the sale of the Company, a merger ...
... has appointed Andrew Chisholm to the position of Vice ... of energy and expertise to Accumetrics. His experience ... of our market penetration," says Timothy I. Still, President ... diagnostics industry and his relationships with distributors make him ...
... (OTC Bulletin Board: BSTC), a biopharmaceutical company developing first ... has received notification from The NASDAQ Stock Market LLC ... on the NASDAQ Global Market. The Company,s common stock ... market open under the symbol "BSTC" and will end ...
Cached Biology Technology:Vasogen Provides Corporate Update 2Vasogen Provides Corporate Update 3Andrew Chisholm Appointed Vice President, Sales and Corporate Accounts at Accumetrics 2BioSpecifics Technologies Corp. Announces Listing on NASDAQ Global Market 2
(Date:7/25/2014)... 25, 2014 Biometrics industry expands ... to digital technology for online & commerce payments while ... (NASDAQ: GOOG ), LifeLock Inc. (NYSE: ... ), Apple Inc. (NASDAQ: AAPL ) and ... NXTD) a biometric authentication company focused on the growing ...
(Date:7/24/2014)... -- Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX) (the "Company") announced the ... Phase 3 study of Zerenex (ferric citrate), the Company,s ... of hyperphosphatemia in patients with end-stage renal disease (ESRD) ... delivery with FErric CiTrate in EsrD) was published online ... of Nephrology ( JASN ). , ...
(Date:7/24/2014)... native animal species for food or commercial food sale, ... in the decline of many species of primates and ... more than half of the species being consumed are ... surveying not only the meat made available for sale ... forest by hunters and brought to villages for consumption, ...
Breaking Biology News(10 mins):Consumer Needs for Identity Theft Security Grows with Popularity of Latest Smart Technology Products - Biometrically Secure Digital Wallet to Replace Credit Card Dependency 2Consumer Needs for Identity Theft Security Grows with Popularity of Latest Smart Technology Products - Biometrically Secure Digital Wallet to Replace Credit Card Dependency 3Consumer Needs for Identity Theft Security Grows with Popularity of Latest Smart Technology Products - Biometrically Secure Digital Wallet to Replace Credit Card Dependency 4Consumer Needs for Identity Theft Security Grows with Popularity of Latest Smart Technology Products - Biometrically Secure Digital Wallet to Replace Credit Card Dependency 5Consumer Needs for Identity Theft Security Grows with Popularity of Latest Smart Technology Products - Biometrically Secure Digital Wallet to Replace Credit Card Dependency 6Zerenex™ (ferric citrate) long-term Phase 3 study results published in JASN 2Zerenex™ (ferric citrate) long-term Phase 3 study results published in JASN 3Zerenex™ (ferric citrate) long-term Phase 3 study results published in JASN 4
... Scientists here have made a major discovery that sheds ... natural killer (NK) cells, powerful but somewhat mysterious components ... line of defense against cancer and infectious diseases. , ... are generated in bone marrow, but Michael Caligiuri, director ...
... vanishingly small realm of molecules and atoms may not ... after all. In fact, research at the National Institute ... version of the optical microscope might be able to ... fraction of the wavelength of visible light. , In ...
... Center scientists have discovered a potential new drug that ... one-third of all cancers. The scientists showed they could ... this new compound, called cysmethynil. , Their finding, reported ... the National Academy of Sciences, is the first step ...
Cached Biology News:Scientists identify new model Of NK cell development 2Scientists identify new model Of NK cell development 3Devising Nano Vision for an Optical Microscope 2Newly Discovered Compound Blocks Known Cancer-Causing Protein 2Newly Discovered Compound Blocks Known Cancer-Causing Protein 3
... discovery projects require screening through a ... clinically relevant data from normal biologic ... is now available to help better ... data flood inherent to biomarker discovery. ...
... Sigmas FLAG Immunoprecipitation kit allows ... elution of an active FLAG-tagged protein. ... affinity gel, which is a highly ... agarose resin. The use of affinity ...
... Shaker , ,Product Information , ... GyroTwister GX-1000 is extremely efficient, yet gentle, ... as well as staining gels, hybridization and ... across a broad range. A nonslip rubber ...
... Data System (CDS) now provides integrated ... data processing and reporting for the ... The companys innovative HPLC instrument has ... of Thermo Scientific Hypersil GOLD 1.9 ...
Biology Products: